Alkem Laboratories Limited — Board Meeting, 12-08-2025: Outcome of Board Meeting

Alkem Laboratories' board approved its consolidated financial results for the quarter ended June 30, 2025. The company reported a revenue from operations of ₹3,371.14 Cr and a net profit of ₹664.26 Cr for the period. EPS stood at ₹55.56.

In strategic moves, Alkem acquired 100% stakes in Adroit Biomed for ₹140 Cr and Bombay Ortho Industries for ₹147 Cr. The company also booked a ₹14.29 Cr gain from selling its Indore facility. These acquisitions did not materially impact the quarter's financials.